It should be noted that almost 39% of tumor samples from patients with untreated SCCHN had overexpression of ErbB2/HER2, which suggests that it can serve as a possible target for therapy [16]. This evidence concerns the gene ERBB2 and head and neck squamous cell carcinoma.